Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Adlai Nortye Ltd prices offering at US$23 per share

<< Previous

Bullboard Posts

Next >>

Comment by fox7mfon Sep 29, 2023 12:06pm

177 Views

Post# 35661850

RE:RE:RE:RE:RE:RE:RE:Adlai Nortye Ltd prices offering at US$23 per share

I'm not speaking for Noteable, but I would suggest that shareholder value certainly isn't the first & foremost goal for glory hound Coffey. Two ph3 trials in PDAC alone. Two more ph3 trials in mBC and (possibly) CRC. Our market cap should be approaching $4b. My opinion only.

<< Previous

Bullboard Posts

Next >>

Sirios Resource discovers visible gold in Quebec